Kathrin Eschke

Helmholtz Centre for Infection Research — Germany

Medicine · Health Sciences

17h-index761citations31works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(22), COVID-19 Clinical Research Studies(8), Herpesvirus Infections and Treatments(6), Animal Virus Infections Studies(5), Cytomegalovirus and herpesvirus research(4)

Publications31 total

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants
Frontiers in Immunology·2024· 4 citedOpen Access
In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPs® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2
Frontiers in Pharmacology·2023· 9 citedOpen Access
Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion release
Science Signaling·2023· 42 cited
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
iScience·2023· 3 citedOpen Access
A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants
2022Open Access
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
Nature Biotechnology·2022· 56 citedOpen Access
Body temperature variation controls pre-mRNA processing and transcription of antiviral genes and SARS-CoV-2 replication
Nucleic Acids Research·2022· 14 citedOpen Access
Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics
Molecular Therapy·2022· 33 citedOpen Access
Macrophages only sense infectious SARS-CoV-2 when they express sufficient ACE2 to permit viral entry, where rapid cytokine responses then limit viral replication
2022· 2 citedOpen Access
Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases
Journal of Virology·2022· 38 citedOpen Access
MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
Cellular and Molecular Immunology·2022· 16 citedOpen Access
Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by Omicron
SSRN Electronic Journal·2022Open Access
Insights into standards of care – dexamethasone and antibodies against COVID-19 in hamster models
2021Open Access
Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)
Science Advances·2021· 44 citedOpen Access
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies
PLoS ONE·2021· 28 citedOpen Access
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Cell Reports·2021· 103 citedOpen Access
Equine Herpesvirus Type 4 (EHV-4) Outbreak in Germany: Virological, Serological, and Molecular Investigations
Pathogens·2021· 31 citedOpen Access
MCMV based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination
2021Open Access
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
Nature Communications·2021· 97 citedOpen Access
Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
2021· 17 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jakob Trimpert(14), Yeonsu Kim(11), Luka Čičin‐Šain(11), Julia M. Adler(9), Azza Abdelgawad(9), Nikolaus Osterrieder(8), Federico Bertoglio(7), M. Zeeshan Chaudhry(7), Michael Hust(7), Linda Brunotte(7), Stephan Ludwig(7), Markus Hoffmann(6), Stefan Pöhlmann(6), Maximilian Ruschig(5), Ulfert Rand(5), Peggy Riese(5), Achim D. Gruber(5), Andrea Kröger(4), Judith Bushe(4), Olivia Kershaw(4)